Submited on: 13 Dec 2011 05:59:08 PM GMT
Published on: 14 Dec 2011 08:50:41 AM GMT
 
Review on Cost-effectiveness of Bazedoxifene
Posted by Dr. Esther Una Cidon on 06 Mar 2013 10:01:23 PM GMT

  • What are the main claims of the paper and how important are they?

    This study assessed the cost effectiveness of bazedoxifene compared with placebo or raloxifene for the treatment of osteoporosis in postmenopausal women.


  • Are these claims novel? If not, please specify papers that weaken the claims to the originality of this one.

    Yes


  • Are the claims properly placed in the context of the previous literature?

    Yes


  • Do the results support the claims? If not, what other evidence is required?

    Yes


  • If a protocol is provided, for example for a randomized controlled trial, are there any important deviations from it? If so, have the authors explained adequately why the deviations occurred?

    Not applicable


  • Is the methodology valid? Does the paper offer enough details of its methodology that its experiments or its analyses could be reproduced?

    Yes


  • Would any other experiments or additional information improve the paper? How much better would the paper be if this extra work was done, and how difficult would such work be to do, or to provide?

    No. The paper is really interesting


  • Is this paper outstanding in its discipline? (For example, would you like to see this work presented in a seminar at your hospital or university? Do you feel these results need to be incorporated in your next general lecture on the subject?) If yes, what makes it outstanding? If not, why not?

    Yes, it is really interesting mainly because of the drugs used to do the study and the interest of this issue nowadays


  • Other Comments:

    NA

  • Competing interests:
    None
  • Invited by the author to review this article? :
    No
  • Have you previously published on this or a similar topic?:
    Yes
  • References:

    PhD with "Cost-effectiveness evaluation of two different strategies of colon cancer follow-up". Uña E and López-Lara F. “Cost and Effectiveness of Follow-up examinations in patients with Colon Cancer (CC) resected for cure”. 2009 Gastrointestinal Cancer Symposium (ASCO American Society of Clinical Oncology). Reviewer of: "International Journal of health care quality assurance" and "ClinicoEconomics and Outcomes Research". World Congress on Gastroenterology and Urology, Omaha (USA). March 12-14, 2012. Cost-effectiveness of radiographic test applied in colorectal cancer screening computed tomography colonography.

  • Experience and credentials in the specific area of science:
    None
  • How to cite:  Una Cidon E .Review on Cost-effectiveness of Bazedoxifene[Review of the article 'Cost Effectiveness Estimate of Bazedoxifene ' by Iglesias A].WebmedCentral 2013;4(3):WMCRW002572
1 2 3 4 5 6 7 8 9
Report abuse
 

1 Is the subject of the article within the scope of the subject category? Yes
2 Are the interpretations / conclusions sound and justified by the data? Yes
3 Is this a new and original contribution? Yes
4 Does this paper exemplify an awareness of other research on the topic? Yes
5 Are structure and length satisfactory? Yes
6 Can you suggest brief additions or amendments or an introductory statement that will increase the value of this paper for an international audience? Yes
7 Can you suggest any reductions in the paper, or deletions of parts? Yes
8 Is the quality of the diction satisfactory? Yes
9 Are the illustrations and tables necessary and acceptable? Yes
10 Are the references adequate and are they all necessary? Yes
11 Are the keywords and abstract or summary informative? Yes
  • Other Comments:

    6 and 9. I think it should be interesting to include a table with absolute values of new vertebral fractures (first year and following), deep vein venous,  physician visits (general practitioner and hospital) and number of radiographs in the population of the Silverman study. This is important to recalculate cost-effectiveness incremental for anyone who read the article.

    5 and 7. The discussion is a bit long, the two studies of Borgström are too much explained.

  • Competing interests:
    No
  • Invited by the author to review this article? :
    Yes
  • Have you previously published on this or a similar topic?:
    No
  • References:
    None
  • Experience and credentials in the specific area of science:

    I participate in Pharmacy and Therapeutics Comitee writing reports of new drugs that included pharmacoeconomic analysis

  • How to cite:  Ortega-Garcia M .Cost effectiveness estimate of bazedoxifene[Review of the article 'Cost Effectiveness Estimate of Bazedoxifene ' by Iglesias A].WebmedCentral 2013;2(12):WMCRW001289
1 2 3 4 5 6 7 8 9
Report abuse